IL2 and acute myeloid leukemia: The first phase I human study (NCT01898793) showed the safety and initial efficacy of allogeneic CIML NK cells, along with concurrent administration of IL-2, in relapsed/refractory (R/R) AML patients (objective response rate - ORR 5/9 patients, including 4 complete responses) (119).